Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.42 |
| ▸ | PPARA | Q07869 | 14/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633424 | 0.91 | SMN1; SMN2 (0.37) | PPARDPPARADGAT1NR3C1THRA | |
| SCHEMBL6035372 | 0.88 | PPARD (0.36) | PPARDPPARADGAT1NR3C1THRA | |
| SCHEMBL6035388 | 0.86 | SMN1; SMN2 (0.37) | PPARDPPARADGAT1NR3C1THRA | |
| SCHEMBL6036355 | 0.84 | ALDH1A1 (0.39) | PPARDPPARADGAT1FABP3 | |
| SCHEMBL6035191 | 0.83 | MRGPRX4 (0.35) | PPARDPPARATHRATHRBRXRA | |
| SCHEMBL6035705 | 0.81 | PPARA (0.45) | PPARDPPARADGAT1PPARG | |
| SCHEMBL6034689 | 0.80 | PPARD (0.36) | PPARDPPARALTB4RFABP3 | |
| SCHEMBL6035777 | 0.80 | SMN1; SMN2 (0.37) | PPARDPPARAPPARGLTB4R | |
| SCHEMBL6035734 | 0.79 | PPARD (0.46) | PPARDPPARANR3C1THRATHRB | |
| SCHEMBL6035370 | 0.79 | GCGR (0.37) | PPARDPPARAPPARGLTB4RFABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARD 2488/4885PPARA 1717/4885DGAT1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.